Journal Mobile Options
Table of Contents
Vol. 10, No. 4, 1999
Issue release date: July–August 1999
Dement Geriatr Cogn Disord 1999;10:245–251
(DOI:10.1159/000017127)

The Role of the Polymorphic Genes Apolipoprotein E and Methylene- tetrahydrofolate Reductase in the Development of Dementia of the Alzheimer Type

Regland B. · Blennow K. · Germgård T. · Koch-Schmidt A.C. · Gottfries C.G.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The gene for apolipoprotein E (APOE) is polymorphic, and its variant APOE4 is a major risk factor for the development of Alzheimer-type dementia (AD). Another risk factor for AD appears to be negative cobalamin balance, which is very common in elderly people. Cobalamin and folate are interdependent and essential components of the one-carbon metabolism. Another important component is methylenetetrahydrofolate reductase (MTHFR), the gene for which is also polymorphic. Thermolabile MTHFR (tMTHFR), a gene variant that reduces the activity of its enzyme, is common in the general population. In the present study, 75% of 140 AD patients had at least one APOE4 allele. The numbers of APOE4 and tMTHFR alleles correlated significantly with the serum folate levels, however, in opposite directions. The significance of this was augmented by an inverse correlation between APOE4 and tMTHFR. Thus, not only MTHFR but also APOE appears to be related to the one-carbon metabolism, suggesting that APOE4 and insufficient one-carbon metabolism may be synergistic risk factors for AD.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Roses AD: Apolipoprotein E in neurology. Curr Opin Neurol 1996;9:265–270.
  2. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM: Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 1985;76:1501–1513.
  3. Poirier J: Apolipoprotein E in animal models of CNS injury and in Alzheimer’s disease. Trends Neurosci 1994;17:525–530.
  4. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–1981.
  5. Sobel E, Louhija J, Sulkava R, Davanipour Z, Kontula K, Miettinen H, Tikkanen M, Kainulainen K, Tilvis R: Lack of association of apolipoprotein E allele ε4 with late-onset Alzheimer’s disease among Finnish centenarians. Neurology 1995;45:903–907.
  6. Joosten E, Lesaffre E, Riezler R, Ghekiere V, Dereymaeker L, Pelemans W, Dejaeger E: Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer’s disease? J Gerontol A Biol Sci Med Sci 1997;52:M76–M79.

    External Resources

  7. Stabler SP, Lindenbaum J, Allen RH: Vitamin B-12 deficiency in the elderly: Current dilemmas. Am J Clin Nutr 1997;66:741–749.
  8. Carmel R: Cobalamin, the stomach, and aging. Am J Clin Nutr 1997;66:750–759.
  9. Marcus DL, Shadick N, Crantz J, Gray M, Hernandez F, Freedman ML: Low serum B12 levels in a hematologically normal elderly subpopulation. J Am Geriatr Soc 1987;35:635–638.

    External Resources

  10. Metz J, Bell AH, Flicker L, Bottiglieri T, Ibrahim J, Seal E, Schultz D, Savoia H, McGrath KM: The significance of subnormal serum vitamin B12 concentration in older people: A case control study. J Am Geriatr Soc 1996;44:1355–1361.
  11. Johnston CS, Thomas JA: Holotranscobalamin II levels in plasma are related to dementia in older people (letter). J Am Geriatr Soc 1997;45:779–780.
  12. Riggs KM, Spiro A III, Tucker K, Rush D: Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306–314.
  13. Lehmann M, Gottfries CG, Regland B: Identification of cognitive impairment in the elderly: Homocysteine is an early marker. Dement Geriatr Cogn Disord 1999;10:12–20.
  14. Goodwin JS, Goodwin JM, Garry PJ: Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983;249:2917–2921.
  15. Wahlin Å, Hill RD, Winblad B, Bäckman L: Effects of serum vitamin B12 and folate status on episodic memory performance in very old age: A population-based study. Psychol Aging 1996;11:487–496.
  16. Regland B: Vitamin B12 deficiency in dementia disorders; doctoral thesis University of Göteborg, Göteborg, 1991.
  17. Carmel R, Gott PS, Waters CH, Cairo K, Green R, Bondareff W, DeGiorgio CM, Cummings JL, Jacobsen DW, Buckwalter G, Henderson VW: The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. Eur J Haematol 1995;54:245–253.
  18. Gomes-Trolin C, Regland B, Oreland L: Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disorders. Eur Neuropsychopharmacol 1995;5:107–114.
  19. Gomes-Trolin D, Gottfries CG, Regland B, Oreland L: Influence of vitamin B12 on brain methionine adenosyltransferase activity in senile dementia of the Alzheimer type. J Neural Transm 1996;103:861–872.

    External Resources

  20. Morrison LD, Smith DD, Kish SJ: Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem 1996;67:1328–1331.
  21. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H: Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry 1998;13:235–239.
  22. McKeever MP, Weir DG, Molloy A, Scott JM: Betaine-homocysteine methyltransferase: Organ distribution in man, pig, and rat and subcellular distribution in the rat. Clin Sci 1991;81:551–556.

    External Resources

  23. Regland B, Gottfries CG: Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down’s syndrome, AIDS and Alzheimer’s disease? Med Hypotheses 1992;38:11–19.
  24. Bottiglieri T, Godfrey P, Flynn T, Carney MWP, Toone BK, Reynolds EH: Cerebrospinal fluid S-adenosylmethionine in depression and dementia: Effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 1990;53:1096–1098.
  25. Lipton SA, Kim WI, Choi YB, Kumar S, D’Emilia DM, Rayudu PV, Arnelle DR, Stamler JS: Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923–5928.
  26. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–113.
  27. Wilcken DEL: MTHFR 677C->T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease. Lancet 1997;350:603–604.
  28. Refsum H, Ueland PM, Nygård O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Med 1998;49:31–62.
  29. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB: Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997;54:1276–1282.
  30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  31. Stabler SP, Lindenbaum J, Savage DG, Allen RH: Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 1993;81:3404–3413.
  32. Wade JPH, Mirsen TR, Hachinski VC, Fisman M, Lau C, Merskey DM: The clinical diagnosis of Alzheimer’s disease. Arch Neurol 1987;44:24–29.
  33. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. JAMA 1997;277:813–817.
  34. Saunders AM, Hulette C, Welsh-Bohmer KA, Schmechel DE, Crain B, Burke JR, Alberts MJ, Strittmatter WJ, Breitner JCS, Rosenberg C, Scott SV, Gaskell PC Jr, Pericak-Vance MA, Roses AD: Specificity, sensitivity and predictive value of apolipoprotein E genotyping in a consecutive autopsy series of sporadic Alzheimer disease. Lancet 1996;348:90–93.
  35. Scott JM, Weir DG: The methyl folate trap. Lancet 1981;ii:337–340.
  36. Browning PJ, Roberts DD, Zabrenetzky V, Bryant J, Kaplan M, Washington RH, Panet A, Gallo RC, Vogel T: Apolipoprotein E (ApoE), a novel heparin-binding protein inhibits the development of Kaposi’s sarcoma-like lesions in BALB/c nu/nu mice. J Exp Med 1994;180:1949–1954.

    External Resources

  37. Vogel T, Gou N, Guy R, Drezlich N, Krutzsch HC, Blake DA, Panet A, Roberts DD: Apolipoprotein E: A potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994;54:299–308.
  38. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE: Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 1994;264:850–852.
  39. Cohen MB, Lipinski JF, Vuckovic A, Prosser E: Blood S-adenosyl-L-methionine levels in psychiatric disorders. Am J Psychiatry 1982;139:229–231.

    External Resources

  40. Mudd SH, Poole JR: Labile methyl balances for normal humans on various dietary regimens. Metabolism 1975;24:721–735.
  41. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J Jr: Plasma total homocysteine in healthy subjects: Sex-specific relation with biological traits. Am J Clin Nutr 1996;64:587–593.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50